Crewe Advisors’s CONMED CNMD Stock Holding History

Crewe Advisors’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1	Closed	-$110	–	949
2023 Q4	$110	Buy	+1	New	+$103	﹤0.01%	407

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Crewe Advisors's CNMD Position: Q1 2024 in Review

Crewe Advisors sold out of CONMED (CNMD) in Q1 2024, closing a stake of 1 share — an estimated $110 sold.

Crewe Advisors first reported a position in CNMD in Q4 2023 and held it in 1 quarter. The position peaked at $110 in Q4 2023. 298 funds tracked by Wall St. Rank hold CNMD as of Q1 2024.

Crewe Advisors reported no remaining CONMED position as of Q1 2024 after selling out during the quarter.
Crewe Advisors sold 1 CONMED share in Q1 2024, an estimated $110.
Crewe Advisors first reported a position in CONMED in Q4 2023 and held it in 1 quarter.
Crewe Advisors's CONMED position peaked at $110 in Q4 2023.
298 funds tracked by Wall St. Rank held CONMED as of Q1 2024.

Based on Crewe Advisors's 13F filing for Q1 2024, filed 14 May 2024.